Jing Na, Ma Ming-Wei, Gao Xian-Shu, Liu Jian-Ting, Gu Xiao-Bin, Zhang Min, Zhao Bo, Wang Yu, Wang Xian-Ling, Jia Hai-Xia
Department of Radiation Oncology, Shanxi Cancer Hospital and the Affiliated Cancer Hospital of Shanxi Medical University, Taiyuan, China.
Department of Radiation Oncology, Peking University First Hospital, Beijing, China.
Ann Transl Med. 2020 Nov;8(21):1447. doi: 10.21037/atm-20-413.
The purpose of this study was to develop prognostic nomograms from a cohort of patients with triple-negative breast cancer (TNBC) with histology of infiltrating duct carcinoma (IDC) by correlating their clinical and pathological parameters with the rates of disease-free survival (DFS) and overall survival (OS).
We retrospectively analyzed TNBC patients with histology of IDC at our institution between 2009 and 2012. Age, family history, menopausal status, surgery type, T stage, N stage, histological grade, vascular invasion, perineural invasion, cytokeratin 5/6 status, Ki-67 expression, and epithelial cadherin (E-cadherin) status were analyzed. Predictors were used in multivariable logistic regression analysis to develop a nomogram to predict DFS and OS rates. The nomograms were then subjected to internal validation, with external validation of the nomogram for predicting OS using separate cohorts of TNBC patients known from the Cancer Genome Atlas (TCGA) database. Using the concordance index (C-index) with calibration curves, the predictive accuracy and discriminative ability were calculated.
A total of 242 eligible TNBC patients were included for analysis. The median follow-up time was 70.73 months. Of the patients, 32.6%, 42.6%, and 24.8% had stage I, II, and III disease, respectively. The 3- and 5-year survival rates were 81.0% and 76.5% for DFS, and 86.5% and 81.1%, for OS, respectively. Age, T stage, N stage, and E-cadherin status were found to be risk factors. The nomograms based on those risk factors accurately predicted the 3- and 5-year survival rates. The C-index was 0.798 and 0.821 for DFS and OS, respectively. Besides, the nomogram for OS showed relatively reliable performance in stratifying different risk groups of patients in training and validation cohorts identified from the TCGA database. The C-index reached 0.843. DFS validation was not completed, as there was insufficient data.
Using clinicopathological information, we produced a prognostic nomogram that accurately predicts the 3- and 5-year DFS and OS for patients with TNBC with histology of IDC. More external confirmation is required.
本研究的目的是通过将三阴性乳腺癌(TNBC)伴浸润性导管癌(IDC)组织学类型患者的临床和病理参数与无病生存率(DFS)和总生存率(OS)相关联,开发预后列线图。
我们回顾性分析了2009年至2012年在本机构就诊的组织学类型为IDC的TNBC患者。分析了年龄、家族史、绝经状态、手术类型、T分期、N分期、组织学分级、血管侵犯、神经周围侵犯、细胞角蛋白5/6状态、Ki-67表达以及上皮钙黏蛋白(E-cadherin)状态。将预测因素用于多变量逻辑回归分析,以开发预测DFS和OS率的列线图。然后对列线图进行内部验证,并使用来自癌症基因组图谱(TCGA)数据库的另一组TNBC患者对预测OS的列线图进行外部验证。使用一致性指数(C指数)和校准曲线计算预测准确性和判别能力。
共纳入242例符合条件的TNBC患者进行分析。中位随访时间为70.73个月。患者中,分别有32.6%、42.6%和24.8%处于I期、II期和III期疾病。DFS的3年和5年生存率分别为81.0%和76.5%,OS的3年和5年生存率分别为86.5%和81.1%。发现年龄、T分期、N分期和E-cadherin状态为危险因素。基于这些危险因素的列线图准确预测了3年和5年生存率。DFS和OS的C指数分别为0.798和0.821。此外,OS列线图在对从TCGA数据库中识别出的训练和验证队列中的不同风险组患者进行分层方面表现出相对可靠的性能。C指数达到0.843。由于数据不足,DFS验证未完成。
利用临床病理信息,我们制作了一个预后列线图,可准确预测组织学类型为IDC的TNBC患者的3年和5年DFS及OS。需要更多的外部验证。